Blastic plasmacytoid dendritic cell neoplasm
Revision as of 01:44, 25 February 2020 by Warner-admin (talk | contribs) (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov")
| Section editor | |
|---|---|
 |
Martin W. Schoen, MD, MPH Saint Louis University St. Louis, MO  mwschoen
|
1 regimens on this page
1 variants on this page
|
All lines of therapy
Tagraxofusp monotherapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Frankel et al. 2014 (STU 012013-061) | NR | Phase I/II, <20 pts |
| Pemmaraju et al. 2019 (STML-401-0114) | 2014-2017 | Phase I/II (RT) |
Chemotherapy
- Tagraxofusp (Elzonris) 12 mcg/kg IV over 15 minutes once per day on days 1 to 5
21-day cycles
References
- STU 012013-061: Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. link to original article link to PMC article PubMed
- STML-401-0114: Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. link to original article contains verified protocol PubMed